Systemic Mastocytosis Drug Development- Pipeline Analysis Report

Systemic Mastocytosis Drug Development- Pipeline Analysis Report

  • May 2018 •
  • Report ID: 5390316 •
  • Format: PDF
systemic mast cell disease (SMCD) is a gastrointestinal complication, where gene mutation causes excessive mast cell accumulation in liver, spleen, bone marrow. Symptoms include diarrhea, abdominal pain, rashes, breath shortness and fainting.

Around 15 companies and universities are focusing on developing treatment options for Systemic Mastocytosis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Systemic Mastocytosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Systemic Mastocytosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Systemic Mastocytosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.